lasofoxifene has been researched along with Breast Cancer in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 18 (75.00) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Arriola, MW; Brown, TA; Cameron, KO; Cole, MJ; Crawford, DT; Da Silva Jardine, P; Ebbinghaus, CF; Elliott, NC; Gauthier, JW; Ke, HZ; Newhouse, BN; Nickerson, DF; Pan, LC; Pirie, CM; Qi, H; Reinhold, AR; Rosati, RL; Simmons, HA; Sweetnam, PM; Thompson, DD; Tjoa, CM; Tkalcevic, GT; Toler, SM | 1 |
| Gutgesell, LM; Karumudi, B; Lee, S; Lu, Y; Thatcher, GR; Tonetti, DA; Wang, Y; Xiong, R; Zhao, H; Zhao, J | 1 |
| Chang, YF; Fanning, SW; Green, B; Greene, GL; Greene, ME; Komm, B; Kurleto, JD; Lainé, M; Phung, L | 1 |
| Pinkerton, JV; Thomas, S | 1 |
| Briarava, M; Mocellin, S; Nitti, D; Pilati, P | 1 |
| Bodine, PV; Chang, KC; Komm, BS; Nagpal, S; Wang, Y | 1 |
| Armstrong, RA; Cummings, SR; Delmas, PD; Eastell, R; Ensrud, K; Goldstein, S; Kendler, D; LaCroix, AZ; Lee, A; Neven, P; Powles, T; Reid, DM; Sriram, U; Thompson, DD; Thompson, J; Vukicevic, S; Zanchetta, J | 1 |
| Becker, C | 1 |
| Silverman, SL | 1 |
| Armstrong, R; Barrett-Connor, E; Cauley, J; Cummings, S; Eastell, R; Ensrud, K; LaCroix, A; Reid, DM; Thompson, DD; Thompson, JR; Vukicevic, S; Welty, F | 1 |
| Allred, DC; Armstrong, R; Cummings, SR; Curto, M; Eastell, R; Ensrud, KE; Goss, P; LaCroix, AZ; Lee, A; Neven, P; Osborne, CK; Powles, T; Reid, DM; Thompson, DD; Thompson, JR; Vukicevic, S; Wolter, K | 1 |
| Vogel, VG | 1 |
| Schmidt, C | 1 |
| Hamilton, CJ; Jamal, SA; Swan, VJ | 1 |
| Archer, DF | 1 |
| Powles, T | 1 |
| Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H | 1 |
| Hadji, P | 1 |
| Cuzick, J; Sestak, I | 1 |
| Calaf Alsina, J; Coronado Martín, PJ | 1 |
| Ke, HZ; Maeda, T; Simmons, H; Thompson, D | 1 |
| Goldstein, SR | 1 |
| Gajdos, C; Jordan, VC | 1 |
11 review(s) available for lasofoxifene and Breast Cancer
| Article | Year |
|---|---|
Use of SERMs for treatment in postmenopausal women.
Topics: Breast Neoplasms; Clinical Trials as Topic; Dyspareunia; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Toremifene | 2014 |
Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Aged; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Norpregnenes; Piperidines; Postmenopause; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2016 |
New selective estrogen receptor modulators (SERMs) in development.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Indoles; Osteoporosis; Piperidines; Pyrrolidines; Risk Factors; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Thiophenes | 2010 |
Lasofoxifene in osteoporosis and its place in therapy.
Topics: Bone Density; Bone Resorption; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Drug Approval; Europe; Female; Humans; Middle Aged; Musculoskeletal Diseases; Osteoporosis, Postmenopausal; Pyrrolidines; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Women's Health | 2010 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles | 2011 |
The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes | 2012 |
[Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation, Preclinical; Endometrial Neoplasms; Endometrium; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Menopause; Multicenter Studies as Topic; Organ Specificity; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Thromboembolism | 2013 |
[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Topics: Animals; Bone Density; Breast Neoplasms; Cholesterol; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Mice; Osteoporosis, Postmenopausal; Pyrrolidines; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Transcription, Genetic; Uterus | 2004 |
Lasofoxifene: CP 336156, CP-336156.
Topics: Adult; Aged; Animals; Atrophy; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Musculoskeletal Diseases; Osteoporosis; Pyrrolidines; Rats; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Vaginal Diseases | 2005 |
Not all selective estrogen response modulators are created equal: update on lasofoxifene.
Topics: Animals; Bone Density; Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes | 2006 |
Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cinnamates; Drug Design; Forecasting; Humans; Molecular Biology; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Toremifene; Treatment Outcome | 2002 |
3 trial(s) available for lasofoxifene and Breast Cancer
| Article | Year |
|---|---|
Lasofoxifene in postmenopausal women with osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tetrahydronaphthalenes; Venous Thromboembolism | 2010 |
Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Risk Factors; Stroke; Tetrahydronaphthalenes; Treatment Outcome | 2010 |
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Double-Blind Method; Estradiol; Female; Fractures, Bone; Humans; Incidence; Mammography; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Primary Prevention; Pyrrolidines; Receptors, Estrogen; Risk Assessment; Selective Estrogen Receptor Modulators; Sex Hormone-Binding Globulin; Tetrahydronaphthalenes; Treatment Outcome; United States | 2010 |
10 other study(ies) available for lasofoxifene and Breast Cancer
| Article | Year |
|---|---|
Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
Topics: Administration, Oral; Animals; Biological Availability; Bone Density; Breast Neoplasms; Cell Division; Cholesterol; Estrogen Antagonists; Ethinyl Estradiol; Female; Humans; Hypolipidemic Agents; Neoplasms, Hormone-Dependent; Organ Size; Ovariectomy; Pyrrolidines; Rats; Receptors, Estrogen; Tetrahydronaphthalenes; Tumor Cells, Cultured; Uterus | 1998 |
Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice, Nude; Models, Molecular; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Thiophenes | 2017 |
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Models, Animal; Estrogen Receptor alpha; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mutation; Neoplasm Metastasis; Piperazines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome | 2021 |
Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogens, Conjugated (USP); Female; Gene Expression; Gene Expression Profiling; Humans; Indoles; Oligonucleotide Array Sequence Analysis; Pyrrolidines; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Signal Transduction; Tetrahydronaphthalenes; Up-Regulation | 2010 |
Another selective estrogen-receptor modulator for osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism | 2010 |
Tipping the balance for the primary prevention of breast cancer.
Topics: Adult; Age Factors; Aged; Anticarcinogenic Agents; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Confounding Factors, Epidemiologic; Estradiol; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Risk Assessment; Sample Size; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome | 2010 |
Third-generation SERMs may face uphill battle.
Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Estradiol; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Patents as Topic; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; United States; United States Food and Drug Administration | 2010 |
The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
Topics: Breast Neoplasms; Estrogen Antagonists; Estrogens; Female; Female Urogenital Diseases; Humans; Indoles; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes | 2011 |
Prevention of breast cancer by newer SERMs in the future.
Topics: Breast Neoplasms; Female; Humans; Piperidines; Pyrrolidines; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Thiophenes | 2011 |
Preventive therapy for breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Meta-Analysis as Topic; Middle Aged; Piperidines; Preventive Medicine; Pyrrolidines; Raloxifene Hydrochloride; Receptor, ErbB-2; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2012 |